To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
NCT ID: NCT03644186
Last Updated: 2024-12-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
147 participants
INTERVENTIONAL
2019-04-16
2023-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The neo-adjuvant setting was chosen to evaluate these therapy combinations in a short time-frame and to provide access to biomaterial both at baseline and after the end of the treatment, at surgery. Biopsy specimens will be analyzed at the end of the trial by gene-expression profiling to assess RBsig status. This marker may represent a tool to identify the participants who are more likely to benefit from a chemotherapy-free regimen in this population.
Palbociclib is a potent, highly selective, reversible, orally active, inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6), therefore inhibiting cell growth and can be safely and effectively administered to older patients without need for dose adjustment based solely on age. Treatment de-escalation, namely harnessing and taking maximum advantage of targeted therapies vs conventional treatment (chemotherapy) in order to limit side effects, is particularly appealing in the older population.
Clinical data from the HR positive /HER2 negative setting show that combinations of palbociclib and letrozole are safe and effective. These combinations have not yet been tested in the HR positive /HER2 positive population that the investigators include in this trial. However, combinations of trastuzumab and endocrine treatment (ET), including letrozole have shown to be safe and to have some additional activity compared to ET alone in the HR positive /HER2 positive population. Therefore, the role of palbociclib in addition to letrozole and trastuzumab plus pertuzumab needs to be further studied.
Current standard of care for treatment of HER2 positive BC incorporates chemotherapy and anti-HER2 agents, with chemotherapy regimens of sequential anthracyclines and taxanes, used as single agents or in combination with other chemotherapy drugs. Trastuzumab is often administered concurrently with a single agent taxane to avoid the possible additive cardiac toxicity of combinations of anthracycline containing regimens and trastuzumab.
A regimen of weekly paclitaxel and trastuzumab plus pertuzumab was chosen as the comparator arm in this trial. More aggressive chemotherapy may not be justified in this population and trial participants may receive additional treatment after surgery, at the discretion of the treating doctor.
Preclinical and clinical rationale exists to support the proposal that palbociclib may represent a valuable option for increasing the activity of ET and anti-HER2 agents, such that a triple combination with these agents could prove superior to a standard treatment with chemotherapy and anti-HER2 agents.
The investigators hypothesize that the combination of palbociclib, letrozole and trastuzumab plus pertuzumab proposed in this trial will be more efficacious compared to the combinations of anti-HER2 agents and ET reported in other trials.
In 2019, it is estimated that of 260,600 newly diagnosed cases of invasive breast cancer in the United States, 82% occurred in women aged 50 or over. Furthermore, of the 41,760 breast cancer-related deaths in the same year, 90% occurred in this predominantly post-menopausal age group. Around 40% of BCs occur in women aged 65 and older. Of these, 10-15% have tumors that overexpress HER2. Elderly patients are generally underrepresented in clinical trials and may benefit from anti-HER2 agents as much as the younger population. Post-menopausal patients with HR positive /HER2 positive BC represent a unique group of patients with an unmet clinical need. This population is the focus of the TOUCH trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paclitaxel plus trastuzumab and pertuzumab
Receiving paclitaxel 80mg/m2 i.v. on day 1, 8, 15 every 28 days for 4 cycles, trastuzumab 600mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for a total of 5 doses.
Paclitaxel
Chemotherapy plus HER2 Blockade
Trastuzumab
Chemotherapy plus HER2 Blockade
Pertuzumab
Chemotherapy plus HER2 Blockade
Palbociclib plus letrozole plus trastuzumab and pertuzumab
Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
Palbociclib
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Letrozole
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Trastuzumab
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Pertuzumab
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paclitaxel
Chemotherapy plus HER2 Blockade
Trastuzumab
Chemotherapy plus HER2 Blockade
Pertuzumab
Chemotherapy plus HER2 Blockade
Palbociclib
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Letrozole
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Trastuzumab
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Pertuzumab
CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Early breast cancer with tumor size \>1 cm (as measured by at least one of the required examination methods of clinical examination, mammography and ultrasonography);
* No clinical evidence of regional lymph node metastasis (via physical and/or radiological exam) (cN0) OR
* Clinical evidence of cN1 status, defined by nodal involvement limited to clinically or radiologically detectable metastasis to movable ipsilateral level I, II axillary lymph node(s)
* No evidence of metastasis (M0).
2. Postmenopausal, defined by women with:
* Prior bilateral surgical oophorectomy; OR
* Amenorrhea and age ≥60 years; OR
* Age \<60 years and amenorrhea for 12 or more consecutive months in the absence of alternative pathological or physiological cause (including chemotherapy, tamoxifen, toremifene, ovarian suppression, or hormonally-based contraception) plus FSH and serum estradiol levels within the laboratory's reference ranges for postmenopausal women
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
4. Primary tumor must have positive estrogen receptor (ER) ≥10%
5. Primary tumor must be HER2-positive (by IHC and/or ISH)
6. Baseline LVEF ≥55% measured by Echocardiography (preferred) or MUGA scan
7. Normal hematologic status:
* Absolute neutrophil count ≥1500/mm3 (1.5 × 109/L);
* Platelets ≥100 × 109/L;
* Hemoglobin ≥9 g/dL (≥90 g/L).
8. Normal renal function: serum creatinine ≤1.5 ULN
9. Normal liver function:
* Serum total bilirubin ≤1.5 × upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\<2 × ULN) is allowed;
* AST or ALT ≤2.5 × ULN;
* Alkaline phosphatase ≤2.5 × ULN.
10. Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.
11. The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
12. The patient agrees in writing to make tumor (mandatory diagnostic core biopsy and surgical specimen) available for submission for central pathology review and to conduct translational studies as part of this protocol.
Exclusion Criteria
2. Inflammatory breast cancer
3. Bilateral invasive breast cancer
4. Received any prior treatment for primary invasive breast cancer
5. Any active tumor of non-breast-cancer histology
6. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA functional classification ≥II), cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
7. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety
8. Contraindications or known hypersensitivity to any of the trial medications or excipients
9. Treatment with any investigational agents within 30 days prior to expected start of trial treatment
10. Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post major bowel resection
11. Evidence via physical and/or radiological exam of cN2 or cN3 nodal involvement defined by: metastasis to ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted, OR involvement of ipsilateral infraclavicular, internal mammary and/or supraclavicular lymph node(s)
12. History of extensive disseminated/bilateral or known presence of interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis. A history of prior radiation pneumonitis is not considered an exclusion criterion.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Hoffmann-La Roche
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Biganzoli, MD
Role: STUDY_CHAIR
USL4 Hospital of Prato, Italy
Etienne Brain, MD
Role: STUDY_CHAIR
Institut Curie, Paris, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ Klina, Augustijinslei 100
Brasschaat, , Belgium
Jules Bordet Institute
Brussels, , Belgium
CHR de la Citadelle, Boulevard du XIIe de Ligne, 1
Liège, , Belgium
Clinique Saint- Joseph, Rue de Hesbaye 75
Liège, , Belgium
Clinique Saint Elizabeth, Place Louise Godin 15
Namur, , Belgium
AZ Nikolaas, Moerlandstrat 1
Sint-Niklaas, , Belgium
Institut Sainte Catherine
Avignon, , France
Institut Bergonié
Bordeaux, , France
Centre Hospitalier Le Mans
Le Mans, , France
Centre Léon Berard
Lyon, , France
ICM Val d'Aurelle
Montpellier, , France
Institut de Cancérologie de l'Ouest (ICO)
Nantes, , France
Centre Antoine Lacassagne
Nice, , France
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, , France
Institut Curie - Site de Paris
Paris, , France
Centre Hospitalier Annecy Genevois
Pringy, , France
Centre Eugène Marquis
Rennes, , France
Centre Henri Becquerel
Rouen, , France
Institut Curie - Site Saint Cloud
Saint-Cloud, , France
Clinique Pasteur
Toulouse, , France
Institut Claudius Regaud
Toulouse, , France
Clinica Oncologica-Ospedali Riuniti Ancona, Via Conca n.71,
Torrette, Ancona, Italy
Istituto scientifico Romagnolo per lo studio e la cura,Via Piero Maroncelli 40
Meldola, Forli, Italy
U.O Medicina Oncologica Ospedale di Carpi, Via G. Molinari, 2
Carpi, Modena, Italy
Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2
Aviano, Pordenone, Italy
ASO "SS Antonio e Biagio Cesare Arrigo, Via Venezia 16
Alessandria, , Italy
Ospedali Riuniti di Bergamo, A.O.Papa Giovanni XXIII, Piazza OMS1
Bergamo, , Italy
Ospedale S. Orsola-Malpighi, Viale Ercolani 4/2
Bologna, , Italy
Comprensorio Sanitario Bolzano, Via Lorenz Bohler, 5
Bolzano, , Italy
ASST Spedali Civili Brescia, Piazzale Spedali Civili n.1
Brescia, , Italy
E.O. Ospedali Galliera, Mura delle Cappuccine, 14
Genova, , Italy
Ospedale Policlinico San Martino,Largo Rosanna Benzi,10
Genova, , Italy
Ospedale Civile di Lecco,Via della Filanda 14
Lecco, , Italy
Milano, IEO, Via Ripamonti 435
Milan, , Italy
Università del Piemonte Orientale - SCDU Oncologia, Corso Mazzini 18
Novara, , Italy
Azienda Ospedaliero-Universitaria di Parma, via Gramsci 14
Parma, , Italy
Istituti Clinici Scientifici Maugeri SpA-SB,Via Salvatore Maugeri N° 10
Pavia, , Italy
A.O. Universitaria Pisana Ospedale Santa Chiara Pisa, Via Roma 67
Pisa, , Italy
Hospital of Prato, Via Dolce dei Mazzamuti, 7
Prato, , Italy
Santa Maria delle Croci Hospital, Viale Randi 5
Ravenna, , Italy
UO Oncologia, Rimini Hospital, Via Settembrini 2
Rimini, , Italy
Azienda Ospedaliero-Universitaria di Udine, Piazzale S.M. Misericordia 15
Udine, , Italy
AO Universitaria Ospedale Di Circolo e Fondazione,v.le L. Borri, 57
Varese, , Italy
Kantonsspital Baden AG
Baden, Aarau, Switzerland
Universitatsspital Basel, Petersgraben 4
Basel, Canton of Basel-City, Switzerland
Kantonsspital Winterthur
Winterthur, Canton of Zurich, Switzerland
University Hospital Zurich, Frauenklinikstrasse 10
Zurich, Canton of Zurich, Switzerland
Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, IOSI
Bellinzona, Canton Ticino, Switzerland
Brustzentrum Thurgau / Kantonsspital Frauenfeld, Pfaffenholzstrasse 4
Frauenfeld, Thurgau, Switzerland
Inselspital Bern
Bern, , Switzerland
HFR Freiburg - Kantonsspital
Fribourg, , Switzerland
University Hospital Geneva
Geneva, , Switzerland
Kantonsspital St. Gallen, Rorschacher Strasse 95
Sankt Gallen, , Switzerland
Brust-Zentrum AG, Seefeldstrasse 214
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012 Apr;13(4):e148-60. doi: 10.1016/S1470-2045(11)70383-7. Epub 2012 Mar 30.
Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev. 2016 Feb;43:19-26. doi: 10.1016/j.ctrv.2015.11.009. Epub 2015 Dec 15.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3.
Demidenko E. Sample size and optimal design for logistic regression with binary interaction. Stat Med. 2008 Jan 15;27(1):36-46. doi: 10.1002/sim.2980.
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303.
Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 2008;10(5):R75. doi: 10.1186/bcr2142. Epub 2008 Sep 9.
Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist. 2014 Oct;19(10):1076-83. doi: 10.1634/theoncologist.2014-0184. Epub 2014 Aug 20.
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009 Nov 20;27(33):5529-37. doi: 10.1200/JCO.2008.20.6847. Epub 2009 Sep 28.
Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A, Migliaccio I. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016 Sep 13;7(42):68012-68022. doi: 10.18632/oncotarget.12010.
Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. Epub 2013 Oct 16.
Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2012 Sep 15;18(18):5110-22. doi: 10.1158/1078-0432.CCR-12-0903. Epub 2012 Jul 18.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan: Protocol Part 1
Document Type: Study Protocol and Statistical Analysis Plan: Protocol Part 2
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-005067-40
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
IBCSG 55-17
Identifier Type: -
Identifier Source: org_study_id